CT News and Research

RSS

Molecular imaging fusion with CT anatomy results in precise localization of parathyroid lesions: Research

SNM's 2010 Image of the Year illustrates the potential of hybrid molecular imaging to provide precise information about the location and function of a condition known as "hyperparathyroidism." Researchers selected this image from more than 1,500 studies presented over the course of four days during SNM's 57th Annual Meeting in Salt Lake City.

16 Jun 2010

Degradable implant stimulates body to regenerate

In a medical emergency, a puncture of the cranium is commonly treated with an implant. While replacements made of titanium merely plug holes, a new kind of degradable implant stimulates the body to regenerate itself: It is custom-fit and disappears to the same extent that the bone regrows.

16 Jun 2010

AMA: 20 percent of medical claims paid incorrectly, wastes billions

The American Medical Association said Monday that private insurers pay 20 percent of physician claims incorrectly in its third annual 'report card' on the insurance industry, The Associated Press reports.

16 Jun 2010

Central Washington Hospital improves patient experience with Toshiba' Vantage Titan MR system

In today's demanding health care environment, many community hospitals require imaging equipment that provides a variety of advanced diagnostic exams with features that improve patient cooperation. To offer a variety of high-quality, comfortable MR exams to its patients, Central Washington Hospital in Wenatchee, Wash., selected Toshiba America Medical Systems' Vantage TitanTM MR system.

15 Jun 2010

CT angiography not necessary in patients suspected with pulmonary embolism

A new study suggests that computed tomography (CT) angiography might be unnecessary in many patients suspected of having pulmonary embolism (PE), based on the results of risk assessment analysis. PE risk assessment could help reduce radiation exposure and costs associated with CT angiography. The results of the study appear in the online edition and August print issue of the journal Radiology.

15 Jun 2010

ASGE Endoscopy Unit Recognition Program honors 48 endoscopy units

The American Society for Gastrointestinal Endoscopy has recognized 48 endoscopy units as part of its program specifically dedicated to promoting quality in endoscopy, in all settings where it is practiced in the United States. The ASGE Endoscopy Unit Recognition Program honors endoscopy units that follow the ASGE guidelines on privileging, quality assurance, endoscopy reprocessing and CDC infection control guidelines.

15 Jun 2010

AMA's support for health law sparks infighting

A fissure has developed in the American Medical Association, the powerful physicians' lobby that backed the health reform bill earlier this year, about support for the sweeping measure, according to news reports.

14 Jun 2010

Research highlights importance of CT scanning in severe asthma patients

A new study led by University of Leicester researchers at Glenfield Hospital suggests that CT scans may be the way forward for monitoring progression of severe asthma as well as checking how it is responding to treatment.

14 Jun 2010

Baron & Budd, P.C. attorney supports Give a Scan Program for lung cancer research

Baron & Budd, P.C. attorney John Langdoc expressed his support and enthusiasm for a new and innovative initiative by the Washington, D.C.-based Lung Cancer Alliance —called Give a Scan—to make CT Scans and clinical data donated by cancer patients easily accessible to lung cancer researchers. LCA would "de-identify" the scans and data before making the information available to researchers.

11 Jun 2010

HL survivors do not receive recommended cancer screening tests: Study

A population-based study of 2,071 Hodgkin lymphoma survivors over 15 years has discovered that while many survivors had multiple X-rays and CT scans years after treatment was finished, they often did not receive recommended cancer screening tests.

11 Jun 2010

Abraxis BioScience presents phase 3 trial data on metastatic malignant melanoma

Abraxis BioScience, Inc. presented trial design information from its ongoing phase 3 registration trial of nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension), in melanoma, an aggressive form of skin cancer that affects more than 68,000 people in the U.S. each year.

11 Jun 2010

New computer program allows early diagnosis of Alzheimer's disease

Researchers of the University of Granada have developed a new computer program that allows early diagnosis of Alzheimer's disease through processed images.

11 Jun 2010

SBUMC uses RapidArc radiotherapy technology to treat cancer patients

A breakthrough external beam radiotherapy technology that is fast, precise, and has optimal dose delivery to targeted tumors while limiting damage to surrounding normal tissue, is the latest radiotherapy weapon that cancer specialists are using at Stony Brook University Medical Center to treat patients.

11 Jun 2010

Botox reduces short-term pain in thoracic outlet syndrome patients

Made popular for its ability to smooth wrinkles when injected into the face, Botox - a toxin known to weaken or paralyze certain nerves and muscles - may have another use that goes beyond the cosmetic.

11 Jun 2010

Researchers develop new computer program for early diagnosis of Alzheimer's disease

Researchers of the University of Granada have developed a new computer program that allows early diagnosis of Alzheimer's disease through processed images. This new system has enhanced successful early diagnosis of Alzheimer's disease up to 90%, which is an important progress within this area of study.

10 Jun 2010

New study finds propofol poses low risk for children undergoing research-driven imaging studies

A new study finds that propofol, a well-known anesthesia medication, has a low occurrence of adverse events for children undergoing research-driven imaging studies. The study, led by a pediatric anesthesiologist now at Children's National Medical Center, showed a low incidence of adverse events and no long term complications when propofol was used to sedate children for imaging studies that require them to be still for long periods of time.

10 Jun 2010

TF2 bispecific antibody pretargeted therapy prolongs survival in animal model of human colonic cancer

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that pretargeted therapy with TF2, a bispecific antibody against carcinoembryonic antigen (CEA) and a small peptide, delayed tumor growth and prolonged survival in an animal model of human colonic cancer.

10 Jun 2010

Combination of SIR-Spheres and Sorafenib confers survival benefit for patients with inoperable HCC

A unique combination of liver targeted radioactive microspheres (SIR-Spheres) and a standard-of-care systemic agent (Sorafenib) appears to confer a survival benefit for patients with inoperable primary hepatocellular cancer including those with disease that has spread outside the liver, according to the results of a prospective clinical study presented today at the 46th American Society of Clinical Oncology conference.

10 Jun 2010

Curexo Technology's ROBODOC assists in first commercial hip replacement surgery

Curexo Technology Corporation made history on Wednesday, May 26, 2010 when its next-generation ROBODOC® Surgical System assisted Dr. William Bargar as he performed the first commercial hip replacement surgery on Warren Roberts of Davis, CA. Mr. Roberts had his left hip replacement using this robotic device in 1995 as a part of an FDA study. This recent surgery performed at Sutter General in Sacramento was for Mr. Roberts' right hip.

10 Jun 2010

GE Healthcare presents interim phase 2 study results of fluciclatide

GE Healthcare, a unit of the General Electric Company, today presented interim phase 2 study results of fluciclatide, in collaboration with the National Cancer Institute, a federal research agency and part of the National Institutes of Health. Fluciclatide is an integrin-targeted radiopharmaceutical under development for oncology PET imaging.

10 Jun 2010

CT News and Research

Molecular imaging fusion with CT anatomy results in precise localization of parathyroid lesions: Research

Degradable implant stimulates body to regenerate

AMA: 20 percent of medical claims paid incorrectly, wastes billions

Central Washington Hospital improves patient experience with Toshiba' Vantage Titan MR system

CT angiography not necessary in patients suspected with pulmonary embolism

ASGE Endoscopy Unit Recognition Program honors 48 endoscopy units

AMA's support for health law sparks infighting

Research highlights importance of CT scanning in severe asthma patients

Baron & Budd, P.C. attorney supports Give a Scan Program for lung cancer research

HL survivors do not receive recommended cancer screening tests: Study

Abraxis BioScience presents phase 3 trial data on metastatic malignant melanoma

New computer program allows early diagnosis of Alzheimer's disease

SBUMC uses RapidArc radiotherapy technology to treat cancer patients

Botox reduces short-term pain in thoracic outlet syndrome patients

Researchers develop new computer program for early diagnosis of Alzheimer's disease

New study finds propofol poses low risk for children undergoing research-driven imaging studies

TF2 bispecific antibody pretargeted therapy prolongs survival in animal model of human colonic cancer

Combination of SIR-Spheres and Sorafenib confers survival benefit for patients with inoperable HCC

Curexo Technology's ROBODOC assists in first commercial hip replacement surgery

GE Healthcare presents interim phase 2 study results of fluciclatide

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News